Market Cap ₹4556 Cr.
Stock P/E 85.4
P/B 2.9
Current Price ₹1047.6
Book Value ₹ 359.9
Face Value 10
52W High ₹1258
Dividend Yield 0%
52W Low ₹ 974.5
Entero Healthcare Solutions Limited (NSE:ENTERO) is a medical technology company based in India that develops and manufactures medical devices and disposables. Entero was founded in 2007 and is headquartered in New Delhi. Entero Healthcare operates manufacturing facilities in Manesar, Haryana and has over 500 employees. It focuses on single-use disposable medical devices used in critical care, anesthesia, surgery, dialysis, infusion therapy, obstetrics and gynecology.Entero Healthcare has a strong domestic market presence in India and exports its products to over 30 countries globally. The company is ISO 13485 certified for its quality management system. Entero aims to provide high quality yet affordable medical devices to help improve healthcare access. It is privately held and has received funding from investors such as Sequoia Capital. Entero states its vision is to become a globally trusted medical devices supplier through patient-centric innovation and customization of products for local markets
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2022 | Dec 2023 |
|---|---|---|
| Net Sales | 829 | 993 |
| Other Income | 2 | 2 |
| Total Income | 831 | 994 |
| Total Expenditure | 810 | 964 |
| Operating Profit | 21 | 30 |
| Interest | 13 | 16 |
| Depreciation | 5 | 6 |
| Exceptional Income / Expenses | 0 | 0 |
| Profit Before Tax | 2 | 8 |
| Provision for Tax | -1 | 1 |
| Profit After Tax | 4 | 7 |
| Adjustments | -0 | -0 |
| Profit After Adjustments | 3 | 7 |
| Adjusted Earnings Per Share | 8.1 | 4.2 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|
| Net Sales | 1780 | 2522 | 3300 | 1822 |
| Other Income | 4 | 4 | 6 | 4 |
| Total Income | 1784 | 2527 | 3306 | 1825 |
| Total Expenditure | 1758 | 2498 | 3236 | 1774 |
| Operating Profit | 25 | 29 | 70 | 51 |
| Interest | 20 | 29 | 49 | 29 |
| Depreciation | 16 | 20 | 24 | 11 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 |
| Profit Before Tax | -11 | -20 | -4 | 10 |
| Provision for Tax | 5 | 10 | 7 | 0 |
| Profit After Tax | -15 | -29 | -11 | 11 |
| Adjustments | -0 | -0 | -0 | 0 |
| Profit After Adjustments | -16 | -30 | -12 | 10 |
| Adjusted Earnings Per Share | -1553.7 | -77.7 | -28.1 | 12.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 31% | 0% | 0% | 0% |
| Operating Profit CAGR | 141% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 0% | 0% | 0% | 0% |
| ROCE Average | 5% | 3% | 3% | 3% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Shareholder's Funds | 485 | 561 | 595 |
| Minority's Interest | 2 | 2 | 3 |
| Borrowings | 0 | 37 | 31 |
| Other Non-Current Liabilities | 57 | 63 | 54 |
| Total Current Liabilities | 289 | 462 | 624 |
| Total Liabilities | 833 | 1125 | 1307 |
| Fixed Assets | 189 | 262 | 268 |
| Other Non-Current Assets | 12 | 12 | 16 |
| Total Current Assets | 633 | 851 | 1023 |
| Total Assets | 833 | 1125 | 1307 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 43 | 32 | 47 |
| Cash Flow from Operating Activities | -69 | -35 | -45 |
| Cash Flow from Investing Activities | -31 | -162 | -49 |
| Cash Flow from Financing Activities | 89 | 211 | 73 |
| Net Cash Inflow / Outflow | -11 | 14 | -21 |
| Closing Cash & Cash Equivalent | 32 | 47 | 25 |
| # | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Earnings Per Share (Rs) | -1553.7 | -77.71 | -28.11 |
| CEPS(Rs) | 92.2 | -25.16 | 31.94 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -3174.6 | -150.52 | -166.8 |
| Core EBITDA Margin(%) | 1.21 | 0.97 | 1.94 |
| EBIT Margin(%) | 0.52 | 0.36 | 1.37 |
| Pre Tax Margin(%) | -0.61 | -0.79 | -0.11 |
| PAT Margin (%) | -0.86 | -1.17 | -0.34 |
| Cash Profit Margin (%) | 0.05 | -0.38 | 0.4 |
| ROA(%) | -1.84 | -3.01 | -0.91 |
| ROE(%) | 0 | 0 | 0 |
| ROCE(%) | 1.47 | 1.24 | 4.99 |
| Receivable days | 49.66 | 44.63 | 49.19 |
| Inventory Days | 50.03 | 40.09 | 36.04 |
| Payable days | 21.55 | 18.67 | 21.08 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.32 | 0.32 | 0.28 |
| EV/Core EBITDA(x) | 22.61 | 27.75 | 13.45 |
| Net Sales Growth(%) | 0 | 41.71 | 30.85 |
| EBIT Growth(%) | 0 | -0.36 | 393.99 |
| PAT Growth(%) | 0 | -91.74 | 62.28 |
| EPS Growth(%) | 0 | 95 | 63.83 |
| Debt/Equity(x) | 0.29 | 0.51 | 0.63 |
| Current Ratio(x) | 2.19 | 1.84 | 1.64 |
| Quick Ratio(x) | 1.35 | 1.17 | 1.09 |
| Interest Cover(x) | 0.46 | 0.32 | 0.92 |
| Total Debt/Mcap(x) | 0 | 0 | 0 |
| # | Mar 2024 |
|---|---|
| Promoter | 52.44 |
| FII | 23.3 |
| DII | 2.28 |
| Public | 21.99 |
| Others | 0 |
| Total | 100 |
| # | Mar 2024 |
|---|---|
| Promoter | 2.28 |
| FII | 1.01 |
| DII | 0.1 |
| Public | 0.96 |
| Others | 0 |
| Total | 4.35 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
